In TNBC, the most common adverse events reported in clinical trials with checkpoint inhibitors are similar to those observed with chemotherapy and include anemia, neutropenia, nausea, alopecia, and liver function abnormalities, such as increased alanine aminotransferase (ALT) (Li et al., 2021). This evidence concerns the gene GPT and anemia (phenotype).